BioSyent Inc. (BIOYF)

Market Cap	114.39M +27.3%
Revenue (ttm)	32.94M +20.1%
Net Income	6.47M +15.5%
EPS	0.56 +17.5%
Shares Out	n/a
PE Ratio	17.67
Forward PE	n/a
Dividend	0.15 (1.52%)
Ex-Dividend Date	May 29, 2026

Volume	300
Open	10.02
Previous Close	10.10
Day's Range	10.02 - 10.07
52-Week Range	7.63 - 12.00
Beta	0.64
Analysts	n/a
Price Target	n/a
Earnings Date	May 14, 2026

About BioSyent

BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Country: Canada
• Stock Exchange: OTCMKTS
• Ticker Symbol: BIOYF

Financial Performance

In 2025, BioSyent's revenue was 43.05 million, an increase of 22.90% compared to the previous year's 35.03 million. Earnings were 9.01 million, an increase of 23.96%.

Financial numbers in CAD